TAR-210 not checked
Johnson & Johnson (Janssen) · JNJ-42756493
FollowEvery change as it happens, and a Monday email
Trials
2 active
2 in total · 2 in the EU
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Non-Muscle Invasive Bladder Neoplasms (2 trials)
- Main trialPhase 3
- “The main purpose of this study is to compare the disease-free survival (the length of time after randomization that a participant survives without any signs or symptoms of the cancer returning, or progressing) between Bacillus Calmette-Guérin (BCG) treated participants receiving treatment with TAR-210 versus investigator's choice of intravesical chemotherapy for treatment of high-risk non-muscle-invasive bladder cancer (HR-NMIBC).”In the company’s words, NCT06919965 on ClinicalTrials.gov
- Other names
- JNJ-42756493
Other drugs for Non-Muscle Invasive Bladder Neoplasms
- Cretostimogene GrenadenorepvecCG Oncology, Inc. · Phase 3
- Nogapendekin alfa inbakiceptImmunityBio · Phase 2/3
- NDV-01Relmada Therapeutics, Inc. · Phase 3
- TARA-002Protara Therapeutics · Phase 3
- Alpha1HHamlet Pharma AB · Phase 3
- SasanlimabPfizer · Phase 3
Coming up2
- 6 Apr 2028Phase 3 trial completes · ClinicalTrials.gov
- 28 Jun 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials2
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 6 Apr 2028 | A Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer | |
| Phase 3Recruiting | 28 Jun 2028 | A Study to Evaluate TAR-210 Versus Single Agent Intravesical Cancer Treatment in Participants With Bladder Cancer |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026